Jessica Briscoe, Megan Van Berkel Patel, R Chace Hicks, Nadia Froehling, Darren Hunt, Jessica Parker, Breanna Carter
{"title":"使用高渗盐水治疗脑外伤患者急性肾损伤的相关风险因素:一项回顾性研究。","authors":"Jessica Briscoe, Megan Van Berkel Patel, R Chace Hicks, Nadia Froehling, Darren Hunt, Jessica Parker, Breanna Carter","doi":"10.1177/08971900241279631","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background:</b> Hypertonic saline (HTS) is essential pharmacologic treatment for traumatic brain injury (TBI). Previous studies associate HTS with acute kidney injury (AKI), however evidence in TBIs is limited. <b>Objective:</b> This study examines factors associated with AKI in patients requiring HTS for TBI. <b>Methods:</b> This retrospective study was performed at a Level-1 Trauma, Academic Medical Center. Inclusion criteria were TBI, age ≥12 years, ICU length of stay ≥72 hours, and administration of ≥24 hours of continuous HTS or 500 mL of HTS boluses. The primary outcome was identifying factors associated with AKI. Secondary outcomes included correlation between chloride load and level with development of AKI. Chloride load was calculated from HTS and non-HTS sources. <b>Results:</b> Of 129 patients included, 18 (14%) developed AKI. Maximum sodium level was higher in the AKI group (<i>P</i> < 0.0001). Hyperchloremia (Cl ≥ 115 mEq/L) was more common in the AKI group (100% vs 81%, <i>P</i> = 0.0428). Maximum and change in serum chloride were higher in the AKI group (median 128 vs 123 mEq/L, <i>P</i> = 0.0026 and +24 mEq/L vs +17 mEq/L, <i>P</i> = 0.0084, respectively). Logistic regression analysis indicated an OR 1.095 times higher [95% CI (1.022, 1.172)] for developing AKI for every one mEq/L increase in maximum chloride level and an OR 1.032 [95% CI (1.006, 1.058)] for developing AKI for every 1-year increase in age. There was no difference in total chloride load between groups (<i>P</i> = 0.2143). Non-HTS sources provided more than 40% of total chloride load in both groups. <b>Conclusion:</b> Chloride level, and age may be associated with AKI in TBI patients treated with HTS.</p>","PeriodicalId":16818,"journal":{"name":"Journal of pharmacy practice","volume":" ","pages":"249-255"},"PeriodicalIF":1.0000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Risk Factors Associated With Acute Kidney Injury in Traumatic Brain Injury Patients Treated With Hypertonic Saline: A Retrospective Study.\",\"authors\":\"Jessica Briscoe, Megan Van Berkel Patel, R Chace Hicks, Nadia Froehling, Darren Hunt, Jessica Parker, Breanna Carter\",\"doi\":\"10.1177/08971900241279631\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Background:</b> Hypertonic saline (HTS) is essential pharmacologic treatment for traumatic brain injury (TBI). Previous studies associate HTS with acute kidney injury (AKI), however evidence in TBIs is limited. <b>Objective:</b> This study examines factors associated with AKI in patients requiring HTS for TBI. <b>Methods:</b> This retrospective study was performed at a Level-1 Trauma, Academic Medical Center. Inclusion criteria were TBI, age ≥12 years, ICU length of stay ≥72 hours, and administration of ≥24 hours of continuous HTS or 500 mL of HTS boluses. The primary outcome was identifying factors associated with AKI. Secondary outcomes included correlation between chloride load and level with development of AKI. Chloride load was calculated from HTS and non-HTS sources. <b>Results:</b> Of 129 patients included, 18 (14%) developed AKI. Maximum sodium level was higher in the AKI group (<i>P</i> < 0.0001). Hyperchloremia (Cl ≥ 115 mEq/L) was more common in the AKI group (100% vs 81%, <i>P</i> = 0.0428). Maximum and change in serum chloride were higher in the AKI group (median 128 vs 123 mEq/L, <i>P</i> = 0.0026 and +24 mEq/L vs +17 mEq/L, <i>P</i> = 0.0084, respectively). Logistic regression analysis indicated an OR 1.095 times higher [95% CI (1.022, 1.172)] for developing AKI for every one mEq/L increase in maximum chloride level and an OR 1.032 [95% CI (1.006, 1.058)] for developing AKI for every 1-year increase in age. There was no difference in total chloride load between groups (<i>P</i> = 0.2143). Non-HTS sources provided more than 40% of total chloride load in both groups. <b>Conclusion:</b> Chloride level, and age may be associated with AKI in TBI patients treated with HTS.</p>\",\"PeriodicalId\":16818,\"journal\":{\"name\":\"Journal of pharmacy practice\",\"volume\":\" \",\"pages\":\"249-255\"},\"PeriodicalIF\":1.0000,\"publicationDate\":\"2025-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of pharmacy practice\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/08971900241279631\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/8/30 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of pharmacy practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/08971900241279631","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/30 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
摘要
背景:高渗盐水(HTS)是治疗创伤性脑损伤(TBI)的基本药物疗法。以往的研究表明,高渗盐水与急性肾损伤(AKI)有关,但有关创伤性脑损伤的证据却很有限。研究目的本研究探讨了需要使用 HTS 治疗创伤性脑损伤患者的 AKI 相关因素。方法:这项回顾性研究在一家一级创伤学术医疗中心进行。纳入标准为创伤性脑损伤、年龄≥12 岁、ICU 住院时间≥72 小时、连续使用 HTS ≥24 小时或使用 500 毫升 HTS 栓剂。主要结果是确定与 AKI 相关的因素。次要结果包括氯化物负荷和水平与发生 AKI 的相关性。氯化物负荷由 HTS 和非 HTS 来源计算得出。结果:在纳入的 129 名患者中,有 18 人(14%)发生了 AKI。AKI 组的最高钠含量更高(P < 0.0001)。高氯血症(Cl ≥ 115 mEq/L)在 AKI 组更常见(100% vs 81%,P = 0.0428)。AKI 组血清氯化物的最大值和变化值更高(中位数分别为 128 vs 123 mEq/L,P = 0.0026 和 +24 mEq/L vs +17 mEq/L,P = 0.0084)。逻辑回归分析表明,最大氯化物水平每增加 1 毫升/升,发生 AKI 的 OR 值就增加 1.095 倍 [95% CI (1.022, 1.172)];年龄每增加 1 岁,发生 AKI 的 OR 值就增加 1.032 [95% CI (1.006, 1.058)]。各组之间的总氯化物负荷没有差异(P = 0.2143)。在两组中,非 HTS 来源的氯化物占总氯化物负荷的 40% 以上。结论:氯化物水平和年龄可能与接受 HTS 治疗的创伤性脑损伤患者的 AKI 有关。
Risk Factors Associated With Acute Kidney Injury in Traumatic Brain Injury Patients Treated With Hypertonic Saline: A Retrospective Study.
Background: Hypertonic saline (HTS) is essential pharmacologic treatment for traumatic brain injury (TBI). Previous studies associate HTS with acute kidney injury (AKI), however evidence in TBIs is limited. Objective: This study examines factors associated with AKI in patients requiring HTS for TBI. Methods: This retrospective study was performed at a Level-1 Trauma, Academic Medical Center. Inclusion criteria were TBI, age ≥12 years, ICU length of stay ≥72 hours, and administration of ≥24 hours of continuous HTS or 500 mL of HTS boluses. The primary outcome was identifying factors associated with AKI. Secondary outcomes included correlation between chloride load and level with development of AKI. Chloride load was calculated from HTS and non-HTS sources. Results: Of 129 patients included, 18 (14%) developed AKI. Maximum sodium level was higher in the AKI group (P < 0.0001). Hyperchloremia (Cl ≥ 115 mEq/L) was more common in the AKI group (100% vs 81%, P = 0.0428). Maximum and change in serum chloride were higher in the AKI group (median 128 vs 123 mEq/L, P = 0.0026 and +24 mEq/L vs +17 mEq/L, P = 0.0084, respectively). Logistic regression analysis indicated an OR 1.095 times higher [95% CI (1.022, 1.172)] for developing AKI for every one mEq/L increase in maximum chloride level and an OR 1.032 [95% CI (1.006, 1.058)] for developing AKI for every 1-year increase in age. There was no difference in total chloride load between groups (P = 0.2143). Non-HTS sources provided more than 40% of total chloride load in both groups. Conclusion: Chloride level, and age may be associated with AKI in TBI patients treated with HTS.
期刊介绍:
The Journal of Pharmacy Practice offers the practicing pharmacist topical, important, and useful information to support pharmacy practice and pharmaceutical care and expand the pharmacist"s professional horizons. The journal is presented in a single-topic, scholarly review format. Guest editors are selected for expertise in the subject area, who then recruit contributors from that practice or topic area.